Cosentyx (secukinumab) is a Novartis biologic in the interleukin-17A class, approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. It is unusual among specialty biologics because it comes in two completely different forms: a self-injected pen or syringe you pick up from a specialty pharmacy, and an intravenous solution given in a clinic.
That split matters more than it sounds. The pen runs through your pharmacy benefit and gets a retail-style price. The IV runs through the medical benefit, where the provider buys the drug, administers it, and bills you for both. Same molecule, two entirely different price tags and two entirely different sets of paperwork. Every figure below was verified on September 4, 2026.
What Does Cosentyx Cost Without Insurance?
| Service/Type | Low | Average | High |
|---|---|---|---|
| Pen or syringe, one monthly dose, cash direct from Novartis | $3,434 | $3,554 | $3,674 |
| Pen or syringe, one monthly dose, specialty pharmacy | $7,849 | $7,984 | $8,492 |
| IV vial, 125 mg / 5 mL | $2,244 | $2,262 | $2,279 |
| IV maintenance infusion, 250 mg of drug only | $4,489 | $4,558 | $10,084 |
| Infusion administration, first hour (CPT 96365) | $60 | $223 | $223 |
Start with the pen, because that is what most people get. Novartis states on its Paying for COSENTYX page that the list, or wholesale, price as of January 2026 is $8,492.03 a month for either a 150 mg or a 300 mg dose strength self-injection package. Drugs.com quotes a cash price of $7,983.88 for one 150 mg/mL unit, read the same day.
CMS acquisition-cost data lands in the same neighbourhood. In the National Average Drug Acquisition Cost file effective August 19, 2026, the 300 mg two-pen Sensoready carton works out to $7,883.60 per dose, the two-syringe carton to $7,848.71, and the single-pen UnoReady 300 mg presentation to $8,176.20. Medicare Part D paid an average of $7,980.67 per claim for the two-pen carton in 2024, its most recent full year of claims data.
The intravenous side is priced separately and much lower per dose, because the IV maintenance dose caps at 300 mg and most patients get less. Novartis lists it at $4,489.34 per infusion. Drugs.com quotes $2,244.34 for one 125 mg vial. Medicare’s Part B payment limit for J3247, “injection, secukinumab, intravenous, 1 mg,” is $18.233 per milligram for the quarter running July 1 through September 30, 2026, which resets on October 1.
What Drives the Price
Novartis prices by dose, not by milligram
This is the strangest fact on the page and Novartis states it plainly: the list price is the same for a 150 mg package and a 300 mg package. Three independent datasets agree. NADAC puts a single 150 mg Sensoready pen at $7,854.32 and a 300 mg two-pen carton at $7,883.60, a difference of under half a percent for twice the drug. Medicare Part D shows the same shape.
The practical consequence is that a dose increase from 150 mg to 300 mg, which FDA labeling allows for psoriatic arthritis and ankylosing spondylitis patients who are still symptomatic, costs almost nothing extra. The consequence in the other direction is worse: dropping to a lower dose saves you nothing.
The pen and the IV are billed under different rules
The pen is a pharmacy-benefit drug. You get a price, you pay it, the specialty pharmacy ships it. The IV is a buy-and-bill medical-benefit drug: the infusion site purchases the vials, gives the infusion, and bills the drug as J3247 plus a separate administration code.
That second bill is where uninsured patients get hurt. In 2024 Medicare claims data, providers submitted an average gross charge of $40.34 per milligram for J3247 against an average allowed amount of $17.19. A 250 mg maintenance infusion carries a gross charge of roughly $10,084 and a Medicare-priced value of about $4,298. If nobody negotiates for you, the number on your statement is the first one.
The administration fee stacks on top
The infusion itself is billed separately. For CPT 96365, intravenous infusion for therapy up to one hour, providers in physician offices submitted an average charge of $222.72 in 2024 against an average Medicare allowed amount of $60.45. A hospital outpatient department typically adds a facility fee on top of that. Cosentyx IV is given over 30 minutes, so one unit of 96365 is the usual charge.
There is no biosimilar and no generic
As of September 4, 2026, FDA’s Drugs@FDA database lists only two secukinumab applications, BLA 125504 and BLA 761349, both held by Novartis Pharmaceuticals Corporation. FDA’s National Drug Code directory, last updated September 2, 2026, shows Novartis as the only labeler of any secukinumab product in the United States. Nothing is coming to undercut the price this year.
Dosing frequency sets the annual number
For plaque psoriasis, labeling calls for 300 mg at weeks 0, 1, 2, 3 and 4, then every 4 weeks. That front-loaded schedule means five doses in the first five weeks. After that it is roughly 13 doses a year, so a maintenance year at list runs about $110,400 and a year at the direct-to-patient cash price runs about $44,600 to $47,800.
Cash Price vs. Insurance
Cosentyx is one of the few specialty biologics where paying cash is genuinely cheaper than the sticker, and it is cheaper by a lot. Novartis announced a direct-to-patient platform on September 29, 2025 and launched it on November 1, 2025, offering cash-paying patients a discount off list price through ASPN Pharmacies, with fulfilment by Thrifty White Pharmacy.
The two Novartis-affiliated pages disagree on the exact figure. Cosentyx.com lists $3,674.44 per self-injectable dose for the Sensoready 150 mg pen, the UnoReady 300 mg pen and the 150 mg prefilled syringe, and $1,837.22 for the 75 mg syringe. The ASPN enrollment site says $3,434 per self-injectable dose. Both were read on September 4, 2026 and both describe the same program, so treat $3,434 to $3,674 as the working range and confirm the number with ASPN before you enrol.
Read the terms before you assume it applies to you. The direct purchase option is an exclusive cash-pay offer and insurance is not accepted. It cannot be combined with any other Novartis coupon, savings card or free-trial program. Patients on a federal health care program agree not to seek reimbursement or count the purchase toward a deductible.
That is the mirror image of the copay card. The Co-Pay Plus program takes eligible patients to as little as $0 a month, but its posted terms say the offer is valid only when used with commercial health insurance and is not available where the health plan provides no coverage for the drug, or where the patient has federal or state benefits such as Medicare, Medicaid, TRICARE or VA. Note also that copay support for infusion administration cost is not available in Rhode Island or Massachusetts.
How to Pay Less
Start with the Novartis direct-to-patient option. For a self-injecting patient with no coverage, this is the single largest saving on the page: roughly 55 to 57 percent off list, paid by card, HSA or FSA, with the drug shipped to you. Enrol at cosentyx.myaspn.com or by phone, and confirm the current price before you pay.
Apply to the Novartis Patient Assistance Foundation if your income qualifies. NPAF is an independent 501(c)(3) that provides certain Novartis medicines at no cost to patients who cannot afford them, are uninsured or have government insurance, and meet income guidelines. Cosentyx is on its supported medication list. Free beats a discount, so apply here first and treat the cash channel as the fallback.
If you have already had the IV and been billed, negotiate the gross charge. The gap between the $40.34 per milligram average submitted charge and the $17.19 average allowed amount in 2024 Medicare data is your entire argument. Ask for an itemized bill, then use the approach in our guide to negotiating medical bills to anchor on what the payer rate actually is.
Check the infusion site’s charity care policy. Nonprofit hospitals are required to have written financial assistance policies, and infusion given in a hospital outpatient department usually falls under them. Our hospital charity care guide walks through who qualifies and how to ask.
Ask whether the pen makes more sense than the IV. That is a clinical decision, not a cost one, but it is worth knowing that IV Cosentyx is only labeled for adults with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis, not for psoriasis or hidradenitis suppurativa. If both routes are open to you, the pen has a cash channel and the IV does not.
Compare the class before you commit. Taltz is the other IL-17A inhibitor and sits at a nearly identical list price with no cash channel. Skyrizi and Humira are different targets with very different dosing intervals, and Humira now has biosimilars. Our fair price tool can check a quoted figure against benchmark data.
If you are between coverage, get a bridge. Novartis runs a Covered Until You’re Covered program that supplies subcutaneous Cosentyx free for up to two years while a coverage denial is appealed, but it requires private insurance and a denied prior authorization, so it does not help the fully uninsured. If you are in that group, a free or sliding-scale clinic is usually the fastest way to get the prescribing relationship you need to apply to NPAF.
The Bottom Line
For an uninsured patient on the pen, the honest cheapest legitimate route is free drug through the Novartis Patient Assistance Foundation if you qualify on income, and the direct-to-patient cash option at $3,434 to $3,674 per dose if you do not. Ignore the copay card entirely, because its own terms exclude you.
For the IV, there is no cash channel at all. Your leverage is the difference between what the provider bills and what an insurer would have paid, and you have to go get it: itemized bill, financial assistance application, then a negotiated rate. Every dollar figure here is a September 2026 snapshot, and the Medicare Part B rate specifically resets on October 1, 2026.